This website uses cookies to store user session information. By using our website you consent to our terms of use. Read more
I agree
"Mobilitas Pluss Postdoctoral Researcher Grant / Mobilitas Pluss järeldoktoritoetus" project MOBJD526
MOBJD526 "Optimization of cell-penetrating peptide based method to deliver microRNA mimics into dendritic cells and target skin inflammation in vivo (15.09.2019−14.01.2020)", Gemma Carreras Badosa, University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine.
MOBJD526
Dendriitrakkudesse sisenevate peptiidide ja mikroRNA-põhiste nahapõletikku leevendavate nanopartiklite optimeerimine in vivo
Optimization of cell-penetrating peptide based method to deliver microRNA mimics into dendritic cells and target skin inflammation in vivo
15.09.2019
14.01.2020
R&D project
Mobilitas Pluss Postdoctoral Researcher Grant / Mobilitas Pluss järeldoktoritoetus
ETIS classificationSubfieldCERCS classificationFrascati Manual classificationPercent
3. Health3.1. BiomedicineB726 Clinical biology 3.1 Basic medicine50,0
3. Health3.11. Biochemistry, Genetics, Microbiology, Biotechnology, Molecular Biology, Cell Biology, Biophysics and Bioinformatics relating to Health StudiesB210 Histology, cytochemistry, histochemistry, tissue culture 3.1 Basic medicine50,0
PeriodSum
15.09.2019−14.01.202013 480,59 EUR
13 480,59 EUR

Krooniliste põletikuliste haiguste raviks on vaja uusi efektiivseid ja säästvaid ravimeid, kuna praegused ravivõimalused ei ole alati tõhusad ja võivad põhjustada kõrvalmõjusid. mikroRNA-146a on kirjeldatud kui põletiku negatiivne regulaator; kuid siiani on mikroRNA-de (miRNA-de) kasutamine terapeutiliste molekulidena piiratud, miRNA miimide transport rakkudesse on ebaefektiivne. Käesoleva projekti eesmärk on kirjeldada miRNA ja kullerpeptiidide (CPP-de) põhjal moodustunud nanoosakeste (NP-d) - CPP-miRNA-NP-de rakkudesse sisenemise mehhanisme. Me keskendume eriti CPP-miRNA-NP-dele, mille on võime siseneda efektiivselt dendriitrakkudesse (DC-desse), sest need NP-d on potentisiaalselt kasutatvad adaptatiivse immuunvastuse moduleerimisel. Lisaks hinnatakse CPP-miRNA-NP-de manustamise ja toime efektiivsust hiire ärritusliku kontaktdermatiidi mudelis. Kokkuvõttes oleme veendunud, et käesoleva projekti käigus suudame formuleerida CPP-miRNA-146a-NP-d, mis on efektiivsed immuunvastuste moduleerimisel DC-des ja hiire naha põletiku mudelis in vivo.
The development of new effective and save therapeutics for chronic inflammatory diseases is needed, as current treatment options are not always effective and might cause adverse effects. microRNA-146a has been described as a negative regulator of inflammation; but to date, microRNA (miRNA) usage as therapeutic molecules has been limited due to inefficient cellular delivery of miRNA mimics. The aim of this project will be to elucidate on the trafficking mechanism of miRNA and cell-penetrating peptides (CPPs) self-formed nanoparticles (NPs) - CPP-miRNA-NPs. We focus especially on CPP-miRNA-NPs that present enhanced efficiency in case of dendritic cell (DCs) transfection, as these NPs have potential to modulate adaptive immune responses. In addition, the delivery and efficiency of CPP-miRNA-NPs will be assessed in a mouse model of skin inflammation. We expect to develop newly formulated CPP-miRNA-146a-NPs efficient in modulation of immune responses in DCs and skin inflammation in vivo.